Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
3.24 (USD) • At close April 17, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0.151 | 0.367 | 0.46 | 0.632 | 0.743 | 0.847 | 0.842 | 0.594 | 0.148 | 0 |
| Gross Profit
| 0 | -0.151 | -0.367 | -0.46 | -0.632 | -0.743 | -0.847 | -0.842 | -0.594 | -0.148 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 19.385 | 16.526 | 24.468 | 29.115 | 31.83 | 37.975 | 38.586 | 46.305 | 29.356 | 11.352 | 0.041 |
| General & Administrative Expenses
| 8.163 | 6.881 | 8.097 | 9.515 | 11.93 | 10.879 | 10.636 | 10.219 | 7.62 | 2.418 | 0.134 |
| Selling & Marketing Expenses
| 0 | -0.151 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 8.163 | 6.73 | 8.097 | 9.515 | 11.93 | 10.879 | 10.636 | 10.219 | 7.62 | 2.418 | 0.134 |
| Other Expenses
| 0 | 0 | 0.587 | 0.235 | 37.459 | 0 | 0 | 0 | 0 | -17.6 | 0 |
| Operating Expenses
| 27.548 | 23.256 | 32.565 | 38.63 | 43.76 | 48.854 | 49.222 | 56.524 | 36.976 | 13.77 | 0.176 |
| Operating Income
| -27.548 | -23.407 | -32.565 | -38.63 | -43.76 | -48.854 | -49.222 | -56.524 | -36.976 | -13.77 | -0.176 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -34.745 | -3.622 | -8.742 | -4.611 | 37.765 | 2.182 | 2.283 | 0.861 | 0.601 | -17.565 | 0 |
| Income Before Tax
| -62.293 | -27.029 | -41.307 | -43.241 | -5.995 | -46.672 | -46.939 | -55.663 | -36.375 | -31.335 | -0.176 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 8.742 | -5.041 | -1.172 | -2.925 | 2.283 | -0.842 | -0.594 | -0.035 | 0 |
| Net Income
| -62.293 | -27.029 | -50.049 | -38.2 | -4.823 | -43.747 | -46.939 | -55.663 | -36.375 | -31.335 | -0.176 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.02 | -0.56 | -1.08 | -0.91 | -0.16 | -1.49 | -1.71 | -2.72 | -2.36 | -1.54 | -1.03 |
| EPS Diluted
| -1.02 | -0.56 | -1.08 | -0.91 | -0.16 | -1.49 | -1.71 | -2.72 | -2.36 | -1.54 | -1.03 |
| EBITDA
| -27.548 | -26.878 | -40.94 | -42.781 | -5.363 | -48.854 | -46.092 | -54.821 | -35.781 | -31.187 | 0.015 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |